NVO is up 5% today at all time high, probably relieved it was non-inferior, not superior to Victoza.
NVO is one of the premiere beneficiaries of The Global Demographic Tailwind. I should have taken advantage of the sell-off following the noise about insulin FoB’s to add it to my portfolio.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”